Left Main Disease and Bifurcation Percutaneous Coronary Intervention: Focus on Antithrombotic Therapy.

MACE-free survival was significantly lower in the group of DAPT duration <6 months (log-rank 29.5, p<0.001).[ 41 ] Furthermore, results from the PRODIGY trial showed that 24-month DAPT was associated with lower occurrence of ST compared with the 6-month arm only in patients with LM or proximal LAD disease (2.8 versus 5.6%; HR 0.45; 95% CI [0.23–0.89]; p=0.02), but not in patients with other lesions, with a highly significant interaction testing (p for interaction=0.002).[ 42 ] In a different approach, triple antiplatelet therapy by adding cilostazol to DAPT provided no additional long-term benefit in real-world patients undergoing bifurcation PCI.

also in 132,142 other papers